Spyre Therapeutics (SYRE) Fundamental Analysis: Revenue, Earnings & Valuation

3.65 / 10

Netural

Fundamental analysis rates SYRE neutral with a 3.6/10 score. Strengths lie in cash‑to‑market value and inventory turnover, while revenue‑to‑market and gross profit margin lag. PB‑ROE is low, indicating limited valuation upside despite solid liquidity.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score1/3

Weight12.47%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.22%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight16.55%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.17%

1M Return-0.63%

PB-ROE

Value1.47

Score0/3

Weight8.33%

1M Return3.23%

Income tax / Total profit (%)

Value0.01

Score2/3

Weight2.21%

1M Return1.04%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.13%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.57%

1M Return4.32%

Asset-MV

Value-0.55

Score2/3

Weight31.99%

1M Return12.22%

Cash-MV

Value0.02

Score2/3

Weight14.70%

1M Return5.94%

Is SYRE fundamentally strong?

SYRE scores 3.65/10 on fundamentals and holds a Fair valuation at present. Backed by its -25.17% ROE, 0.00% net margin, -24.08 P/E ratio, 5.22 P/B ratio, and 37.74% earnings growth, these metrics solidify its Netural investment rating.